"If you don't talk big game, you never get anywhere. If you don't think big, you don't get big. Some people call it egotistical, some people call it high hopes, some people call it confidence. It's all in how you want to dissect it."
-by Vanilla Ice

Saturday, 30 January 2016

Bios Life Slim and Clinical Studies

Clinically Tested, Peer Accepted:
Studied at North America’s Leading Scientific and Medical Research Centers.
Unicity products have been extensively reviewed in peer reviewed clinical studies conducted at several of the most prestigious hospitals and universities in the US and globally. Unicity continues to dedicate a large portion of the company budget to continued science and research.
Unicity’s flagship product, BALANCE (Bios Life SLIM) meets the NCEP guidelines for first-line treatment of primary dyslipidemia. It has also been studied as an adjunct to statins.
Eleven Unicity Products including Bios Life are listed in the PDR (Physician’s Desk Reference).
Unicity products are manufactured in FDA-approved facilities under stringent good manufacturing practices (GMP), as defined by government regulatory procedures. Where applicable, patented and standardized ingredients are used in the formulating and production processes.
Bios Life UNICITY BALANCE – Clinical Studies:
Cleveland Clinic Trial by Dr. Dennis Sprecher
Published in Sprecher DL, Pearce GL (2002) Fiber-multivitamin combination therapy: a beneficial influence on lowdensity lipoprotein and homocysteine Metabolism 51, 1166-70.
Cleveland_Clinic_Trial_Dennis_Sprecher.pdf
Diabetes in Control Study #1 by Steven Freed and David Joffe
Published in Freed S, Joffe D (2000) The Clinical Impact of Fiber Supplementation for the Reduction of Postprandial Blood Glucose and Risk Reduction of Complications from Diabetes Diabetes in Control 12-8.
Diabetes-in-Control-Study_Steven_Freed_David_Joffe.pdf
Diabetes in Control Study #2 by Steven Freed and David Joffe
Published in Freed S, Joffe D (2004) The Clinical Impact of Fiber Supplementation for the Reduction of Postprandial Blood Glucose and Risk Reduction of Complications from Diabetes II Diabetes in Control 212, 17, and Verdegem P, Freed S, Joffe D (2005) The clinical impact of fiber supplementation for the reduction of postprandial blood glucose and reduction of complications from type-2 diabetes Diabetes 54, A425.

Diabetes_in_Control_Study_2.pdf
The Clinical Impact of Fiber Supplementation on Cardio-Vascular Risk Parameters in type-2 Diabetes.Presented by Verdegem P, Freed S, Joffe D. in 6th International Conference on Atherosclerosis, Thrombosis and Vascular Biology. 2005. Washinton, DC, USA. The American Heart Association sent out a press release on the study results.
Abstract  Poster-ADA-2005.pdf – (AHA) American-Heart-Association-Press-Release.pdf
The Clinical Impact of Fiber Supplementation for the Reduction of Postprandial Blood Glucose and Risk Reduction of Complications from Type-2 Diabetes.
Presented by Verdegem P, Freed S, Joffe D. in 65th Scientific Session American Diabetes Association. 2005. San Diego, CA, USA.
Poster-ADA-2005.pdf
Philippines Trial by Dr. Yumul
Presented by Balajadia E, Valerio A, Yumul N. Beneficial effects of Bios Life 2 (Dietary Fiber Supplement) in patients with dyslipidemia. in 34th Annual Convention of the Philippine College of Physicians. 2004.

Phillippines Trial Dr. Yumul.pdf
Utah Trial by Dr. Peter J.E. Verdegem
As published by Verdegem P (2007) Viscous soluble fiber combined with phytosterols and policosanol reduces LDL-c and increases HDL-c in hypercholesterolemia Current Topics in Neutraceutical Research.

Utah Trial.pdf
Utah Trial #2 by Dr. Peter J.E. Verdegem
As presented by Verdegem P, Duenas V, Duenas J, Burke E. LDL- and HLD-cholesterol optimization using phytonutrient combination therapy: first line intervention and adjunct therapy to statins in 1st Asian Preventive Cardiology & Cardiac Rehabilitation Conference. 2006. Hong Kong.

Presented at the 7th International Congress on Coronary Artery Disease, 2007, Venice, Italy.
Utah Trial 2.pdf
Pacific Rim Trial by Dr. Vincent Duenas
Published in Duenas V, Duenas J, Burke E, Verdegem P (2006) A new fiber drink can serve as an adjunct therapy to statin medication in mild hypercholesterolemia ArteriosclerThrombVascBiol 26, e53-e107.

Pacific Rim Trial Vincent Duenas.pdf
A new fiber drink can serve as an adjunct therapy to statin medication in mild hypercholesterolemia.
Presented by Duenas V, Duenas J, Burke E, Verdegem P. in 7th Annual Conference on Arteriosclerosis, Thrombosis and Vascular Biology. 2006. Denver.
Poster-ATVB-2005-1.pdf  Poster for total users group.pdf  Poster Statin User Group.pdf
Texas Trial by Dr. Isabel MartinezPresented by Martinez I, Horne B, Verdegem P. Lipid and glucose optimization using phytonutrient combination therapy in diabetes. in 8th Annual Conference on Arteriosclerosis, Thrombosis and Vascular Biology. 2007. Chicago.

0 comments:

Post a Comment